• Psychadelic-Science-MAPS-MDMA-April-2017

Psychedelic Science 2017: International Gathering of Scientific Experts talking about Psychedelics, Marijuana, MDMA and more…

If you are curious about the health benefits of Psychedelics, you will not want to miss Psychedelic Science 2017. This 6-day event is presented by: MAPS (Multidisciplinary Association for Psychedelic Studies), which is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Also presented by Beckley Foundation, a UK-based think-tank, which, since its creation by Amanda Feilding in 1998, has been at the forefront of global drug policy reform and scientific research into psychoactive substances. More info below

April 19-24, 2017 — Oakland, California

At Psychedelic Science 2017, the international scientific community will come together at the Oakland Marriott City Center in Oakland, Calif., to share and discover new research into the benefits and risks of MDMA, LSD, psilocybin, ayahuasca, ketamine, ibogaine, medical marijuana, and more.

This historic six-day global gathering, featuring three days of conference presentations and three days of workshops, a Sunset Cruise on the San Francisco Bay, the world’s first Psychedelic Comedy Banquet, and much more.

The Three-Day Conference (April 21-23) will feature three simultaneous tracks of presentations by leading and up-and-coming international researchers in the multidisciplinary field of psychedelic science and medicine. Presenters from around the world will share recently completed and ongoing research into the therapeutic, scientific, and spiritual uses of: MDMA, LSD, Ayahuasca, Psilocybin, Ibogaine, Ketamine, Peyote, Medical marijuana, and more…

Ticket prices range from $50 – $450. Tickets to Psychedelic Science 2017 are available here


Many of the workshops have already sold out. Please check the website for availability

Pre-Conference Workshops

Wednesday, April 19, 2017

Psilocybin Research: Therapist Competencies and Therapeutic Processes
Jeffrey Guss, M.D., and Bill Richards, S.T.M., Ph.D.

Holotropic Breathwork™ Workshop: Day 1
Stanislav Grof, M.D., and Stacia Butterfield

Thursday, April 20, 2017

Principles of MDMA-Assisted Psychotherapy for PTSD
Michael Mithoefer, M.D., and Annie Mithoefer, B.S.N.

Immersive Visionary Art
Android Jones

Ayahuasca: From Science to Ceremony
Bia Labate, Ph.D., and colleagues

Psychedelic Neuroscience
David Nichols, Ph.D., and Franz Vollenweider, M.D., with Katrin Preller, Ph.D.

Innovation, Creativity, and the New Psychedelic Culture
James Fadiman, Ph.D., and Thomas B. Roberts, Ph.D.

Holotropic Breathwork™ Workshop: Day 2
Stanislav Grof, M.D., and Stacia Butterfield

Post-Conference Workshops

Monday, April 24, 2017

Ketamine: Science, Therapy, and Transformation
Phil Wolfson, M.D.

Women’s Visionary Council: Psychedelic Culture and Community
Anne Tara Szostek, Annie Oak, M.S., Denis Berry, Mariavittori Mangini, Ph.D., F.N.P

Psychedelic Harm Reduction
Zendo Project

Visionary Art
Alex Grey and Allyson Grey

Integrating Psychedelic Experiences
Ingmar Gorman M.A., Katherine MacLean, Ph.D., Julie Megler, R.N., and Tanya Maté, N.D.



There is a Sunset Cruise and/or Comedy Banquet, which have both SOLD OUT. There’s a waiting list, so you may want to put your name down for it ASAP.



Anthony P. Bossis, Ph.D.
The Varieties of Religious Leaders’ Experiences: The NYU Clinical Trial on the Effects of Psilocybin-Generated Mystical Experience in Religious Leaders

Mary Cosimano, M.S.W
Love and Connection in Psilocybin-Facilitated Research Studies

Rick Doblin, Ph.D.
The Future of Psychedelic Therapy

Amanda Feilding
From Taboo to Treatment: The Evolution of Psychedelic Medicine

Albert Garcia-Romeu, Ph.D.
Optimizing Psilocybin Dosing for Clinical Precision: The Case for Weight-Adjusted Dosing

Roland Griffiths, Ph.D.
Johns Hopkins Psilocybin Research Project: Studies of Mystical Experience, Adverse Effects, Meditation in Healthy Volunteers, and Palliative Effects in Cancer Patients

Stan Grof, M.D.
The Implications of Consciousness Research for Psychiatry, Psychology, and Psychotherapy

Matthew W. Johnson, Ph.D.
Psychedelics as Behavior Change Agents: Addiction Recovery and Beyond

Mendel Kaelen
The Psychological and Neurophysiological Effects of Music in Combination with Psychedelics

Darrick May, M.D.
Examining “Bad Trips”: Acute and Enduring Positive and Negative Consequences of Challenging Experiences with Psilocybin

Michael Mithoefer, M.D., and Annie Mithoefer, B.S.N.
MDMA-Assisted Psychotherapy for PTSD: Lessons from Phase 2 Clinical Trials

David Nichols, Ph.D.
Psychedelic Neuroscience

David Nutt, M.D.
Psychedelic Research at the Beckley/Imperial Research Programme

Marcela Ot’alora, M.A., L.P.C. and Bruce Poulter, R.N., M.P.H.
MDMA as Profound Change Agent: Insights from MDMA-assisted Psychotherapy for PTSD Research

Jordi Riba, Ph.D.
New Findings from Ayahuasca Research
From Enhancing Mindfulness Abilities to Promoting Neurogenesis: New Findings on the Therapeutic Potential of Ayahuasca

Leor Roseman, M.Sc.
Psilocybin-Assisted Therapy for Depression Increases Amygdala Reactivity After Therapy, While Reducing Symptoms

Stephen Ross, M.D., and Gabby Agin-Liebes, Ph.D. Candidate
Psilocybin for Cancer-Related Anxiety and Depression: NYU Phase 2 Randomized Controlled Trial and Proposed Mechanisms

Eduardo Schenberg, Ph.D.
Bringing MDMA-Assisted Psychotherapy to Brazil

Ben Sessa, M.B.B.S., M.D., B.Sc., M.R.C.Psych.
MDMA Therapy: A Child Psychiatrist’s Perspective

Anne C. Wagner, Ph.D., C.Psych.
Combining Cognitive Behavioral Conjoint Therapy for PTSD and MDMA – First Cases and Understanding the MDMA Experience from a Cognitive Behavioral Framework

Phil Wolfson M.D. and Julane Andries L.M.F.T.
MDMA-Assisted Psychotherapy for Anxiety in Life-Threatening Illness

Marc Aixalà, Ph.D.
Psychotherapeutic Intervention in Integration of Difficult Psychedelic Experiences: The ICEERS Support Service

Elena Argento, Ph.D. Candidate
Psychedelic Use Predicts Reduced Suicidality: Findings From a Longitudinal Study of Women Sex Workers in Vancouver, Canada

Selen Atasoy, Ph.D.
Enhanced Improvisation in Brain Processing by LSD: Exploring Neural Correlates of LSD Experience with Connectome-Specific Harmonic Waves

Harriet de Wit, Ph.D.
Ecstasy in the Laboratory: Recent Advances in MDMA Research

Erika Dyck, Ph.D.
Who is Keeping Tabs? LSD Lessons from the Past

James Fadiman, Ph.D., and Sophia Korb, Ph.D.
Microdosing: The Phenomenon, Research Results, and Startling Surprises

Kevin Franciotti
The Use of Psychedelics in the Treatment of Psychotic Disorders

John Hartberg, B.Sc., M.D. Candidate
Ketamine’s Therapeutic Potential: Practical Considerations for Clinical Use

Katherine Hendy, Ph.D.
The Placebo Paradox

Rainer Krähenmann, M.D.
New Findings from the University of Zurich Studies Into the Mechanism of Action of Psilocybin and LSD: Relevance for Treatment of Major Depression and for Enhancement of Psychotherapy

Philippe Lucas, M.A., Suzanne Sisley, M.D, Zach Walsh, Ph.D.
PANEL: Marijuana for PTSD

Ethan Nadelmann, Ph.D.
Drug Policy and Psychedelics

Claudio Naranjo, M.D.
On Psychedelics, Morality, and Virtue

Carla Nasca, Ph.D.
Epigenetic Predictors of Posttraumatic Stress Disorder and New Possibilities for Therapeutic Intervention

Neiloufar Family, Ph.D
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Low Dose LSD: A Phase 1 Study

Elizabeth M. Nielson, Ph.D.
Psychedelic Therapists: Perspectives on the Therapeutic Process in Psilocybin Assisted Therapy

Tomas Palenicek, M.D., Ph.D.
The Effects of Psilocybin on Perception and the Dynamics of Induced EEG/fMRI Correlates of Psychedelic Experience

Samantha K. Podrebarac, M.Sc.
Aftercare Needs Related to Pilot Participant Data from the Ongoing Double Blind Placebo-Controlled Psilocybin for Alcohol Dependence Clinical Trial at NYU

Janis Phelps, Ph.D.
Accredited Certificate Program in Psychedelic-Assisted Therapies and Research at CIIS: Guidelines, Competencies and Outcomes from the Pioneering Year

Milan Scheidegger, M.D., Ph.D., M.A. HPK
Psilocybin Enhances Mindfulness-Related Capabilities in a Meditation Retreat Setting: A Double-Blind Placebo-Controlled fMRI Study

Emmanuelle A. D. Schindler, M.D., Ph.D.
Indoleamine Hallucinogens in the Treatment of Cluster Headache

Paul Stamets, D.Sc
Psilocybin Mushrooms and The Mycology of Consciousness

Thomas Cody Swift, M.A., and Alexander Belser, Ph.D. Candidate
Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological Distress

Zach Walsh, Ph.D.
Psychedelic Therapy and Third-Wave Behaviorism: New Directions for the Prevention of Interpersonal Violence

Emily Williams, M.D.
Exploring Psychoanalytic Themes and Therapeutic Alliance in MDMA-Assisted Psychotherapy

Brad Adams, Ph.D.
Ayahuasca, Psychiatric Distress, and the Meaning of Life: Results from a Pilot Study in Peru

Peter H. Addy, Ph.D.
Clinical Potential of the Plant Salvia Divinorum

Brian T. Anderson
Drug Ethnography and Clinical Trials: Designing a Psilocybin Therapy Protocol

Draulio Barros de Araujo, Ph.D.
Rapid Antidepressant Effects of the Psychedelic Ayahuasca in Treatment-Resistant Depression: A Randomized Placebo-Controlled Trial

Christina Callicott, M.A.
Ethnomedicine Among the Lamista Quechua: History, Innovation and Cultural Revitalization

José Carlos Bouso, Ph.D.
What Do the Spirits Do? Towards an Understanding of the Psychological Mechanisms of Transformation

Thomas Kingsley Brown, Ph.D.
Examining the Psyche in Ibogaine Treatment for Addiction

Ignacio Carrera, Ph.D
Ibogaine and Neurotrophic Factors: GDNF, BDNF and NGF Releasing Properties of Ibogaine and Activity of Novel Ibogaine Analogues

Clancy Cavnar, Psy.D.
An Examination of Psychological Healing with Ayahuasca

Wendy Chapkis, Ph.D.
Medical Marijuana in a Recreational Age

Bruno Ramos Gomes, M.A.
Plant Medicine or Psychedelic Medicine? Understanding the Healing Processes with Ayahuasca and Ibogaine

Dawn D. Davis, M.A.
Conservation Strategies for Sustainability of the Peyote Gardens: What is the Indigenous Approach?

Alexander Dawson, Ph.D.
Peyote’s Race Problem

Benjamin De Loenen, M.A.
Ayahuasca Legal Prosecution Worldwide: Connecting the Dots

Kevin Feeney, Ph.D.
Peyote as Medicine: An Examination of Therapeutic Factors that Contribute to Healing

Ben Feinberg, Ph.D.
Conflict and Transformation in Mazatec and Outsiders’ Views of the Therapeutic Value of Mushroom Use in Huautla

Martin Fortier, Ph.D. Candidate
The Sense of Reality in Hallucinogenic Experiences: A Comparative Study of Serotoninergic and Anti-Cholinergic Plants

Alex K. Gearin, Ph.D.
Ayahuasca and the “Diet”: Some Cross-Cultural Considerations

Paul Glue, M.D., FRC Psych
Ibogaine and Opioid Withdrawal: Does it Work and Is it Safe?

Débora González, Ph.D.
Long-Term Effects of Ayahuasca on the Quality of Life, Well-Being and Health of Western Users: A Longitudinal Study

Shana Harris, Ph.D.
“Ibogaine Works”: Examining the Effectiveness of Psychedelic Drug Treatment from an Anthropological Perspective

O. Hayden Griffin, III, Ph.D.
The Therapeutic Potential of Kratom

Sandor Iron Rope
Indigenous Perspectives on Peyote’s Healing Potentials and Conservation Challenges

Adele Lafrance, C. Psych.
Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences Along the Continuum of Recovery from Eating Disorders

Anja Loizaga-Velder, Ph.D.
Evaluating the Efficacy of Ayahuasca Assisted Treatment for Substance Dependency

Gabor Maté, M.D.
From Jungle To “Civilization”: How Plant Medicines Can Promote Health In a Toxic Culture

Dennis McKenna, Ph.D.
Beyond Ayahuasca: Occurrence and Biological Activities of Some Naturally Occurring ß-carbolines

Diana Negrín, Ph.D.
Peyote Dreams: From Collective Ritual to Personal Treatment?

Jessica Nielson, Ph.D.
Ayahuasca for Posttraumatic Stress Disorder: Assessing Risks and Benefits through Anonymous Community Feedback

Tomas Palenicek, M.D., Ph.D.
The Effects of Psilocybin on Perception and the Dynamics of Induced EEG/fMRI Correlates of Psychedelic Experience

Geoff Noller, Ph.D.
Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study

Melanie Oliveira, Hons. B.Sc.
Examining the Effects of Pre- and Post-Ceremony Factors on Self-reported Therapeutic Experiences to Identify Preliminary Guidelines for Mental Health Clinicians Regarding the Ritualized Use of Ayahuasca

Bruno Rasmussen Chaves, M.D.
Ibogaine in Brazil: Finally Stepping out from the Underground?

Raven Renèe Ray, M.A.
Ayahuasca Treatment Center Safety for the Western Seeker

Stevens Rehen, Ph.D.
Biological Effects of Ayahuasca in Human Neural Stem Cells and Minibrains

Amanda Reiman, Ph.D.
The Use of Cannabis as a Substitute for Opiate and Non-Opiate Based Pain Medication

Jordi Riba, Ph.D.
Salvinorin-A: A Perception-Modifying Drug with a Unique Neurophysiological Profile

Sidarta Ribeiro, Ph.D.
Whole Organisms or Pure Compounds? Entourage Effect versus Drug Specificity

Emilia Sanabria
Healing Encounters: Ayahuasca and the Politics of Knowledge

Constanza Sánchez Avilés, Ph.D.
Ayahuasca Practices as Intangible Cultural Heritage: A New Piece in the Drug Policy Puzzle?

Stacy B. Schaefer, Ph.D.
Peyote: Plant Medicine for the Body, Mind, and Soul

Scott Shannon, M.D., ABIHM
Cannabidiol in the Treatment of Anxiety: A Large Case Series

Jordan Sloshower, M.D., M.Sc.
Integrating Plant Medicines and Psychiatry: Theory and Methods of a Model Clinic

Graham St. John, Ph.D.
DMT, Liminality, and Hyperspace

Joanna Steinhardt, M.A., Ph.D. Candidate
Psychedelic Naturalism: Psilocybin and the Evolution of Amateur Applied Mycology

Luís Fernando Tófoli, Ph.D.
Treating Alcohol-Related Disorders with Ayahuasca

Clare S. Wilkins
A Novel Approach to Detoxification from Methadone Using Low, Repeated, and Cumulative Administering of Ibogaine

Eda Zavala Lopez
Genios and Chullachaquis from the Rainforest Amazon and Their Ways to Cure Human Conditions



Fatal error: Call to undefined function essb_core() in /home3/mattstonenyc/public_html/wp-content/plugins/essb-display-mobile-sharebarcta/essb-display-mobile-sharebarcta.php on line 61